NCT01518400 LIFE Cancer Survivorship Database for Pediatric Cancer
| NCT ID | NCT01518400 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Hospital Los Angeles |
| Condition | Pediatric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2009-02 |
| Primary Completion | 2050-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2009-02 with a primary completion date of 2050-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to develop a mechanism for utilizing the comprehensive clinical database of childhood cancer survivors at Childrens Hospital Los Angeles (CHLA) for research purposes. Using clinical information obtained from follow-up visits of childhood cancer survivors, the database will focus on interventions to improve health status and health-related quality of life in childhood cancer survivors. This study allows for establishment and analyses of a research database for LIFE survivors by the investigators listed herein. Over the last three decades, there has been marked improvement in survival following childhood cancer, with 5-year survival rates now approaching 80%. However, the use of cancer therapy at an early age can result in complications that may not be apparent until years later as the child matures. These resulting complications, called late effects, are principally related to the specific therapy employed and the age of the child at the time the therapy was administered. Late effects may affect virtually every body system and substantially impair quality of life. As many as two-thirds of childhood cancer survivors develop at least one late effect as a result of treatment, and approximately one-third have a late effect classified as severe or life threatening.
Eligibility Criteria
Inclusion Criteria: * Been diagnosed with cancer or similar disease * Been diagnosed with cancer at 21 years of age or younger * Be currently off treatment and disease free
Contact & Investigator
David Freyer, DO, MS
PRINCIPAL INVESTIGATOR
Children's Hospital Los Angeles
Frequently Asked Questions
Who can join the NCT01518400 clinical trial?
This trial is open to participants of all sexes, studying Pediatric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01518400 currently recruiting?
Yes, NCT01518400 is actively recruiting participants. Contact the research team at lgov@chla.usc.edu for enrollment information.
Where is the NCT01518400 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT01518400 clinical trial?
NCT01518400 is sponsored by Children's Hospital Los Angeles. The principal investigator is David Freyer, DO, MS at Children's Hospital Los Angeles. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.